Cytiva, Pall to invest $1.5B in biomanufacturing over next 2 years

By Samantha Black, PhD, ScienceBoard editor in chief

July 27, 2021 -- Cytiva and Pall, both Danaher companies, will make major investments in manufacturing capacity and services at 13 sites around the globe supporting life science customers, totaling $1.5 billion over two years.

The investments include new sites in the U.S. and U.K., and expansion of existing facilities. The announcement follows five strategic acquisitions made by the companies in 2021 (Vanrx, Austar, GoSilico, Precision NanoSystems, and Intermountain Life Sciences) and is in addition to Cytiva's continuing capacity investments, which are estimated to be $500 million.

Specifically, the companies are investing the following:

    • $600 million in chromatography resins (media for analyzing or purifying biomolecules), including the establishment of a new manufacturing site in the U.S.
    • $400 million in cell culture media (liquid or powder forms used to grow and cultivate cells prior to purification), with plans to expand operations in the U.S., U.K., and Austria
    • $300 million in single-use technologies (bioreactor bags for growing cells and syringe filters for scientific research), with plans to expand operations in the U.S. and U.K., as well as fitting out a new facility in Cardiff, Wales
    • $200 million to expand Cytiva and Pall sites across China, the rest of the Asia-Pacific region, Europe, and the U.S.

The companies plan to hire 2,000 people over the next two years at the various facilities.

The investments also address key challenges highlighted in the Global Biopharma Resilience Index, including hiring and training talent, R&D collaboration, supply chain resilience, and manufacturing models.

Pall to develop gene therapy manufacturing platform for Exothera
Filtration, separation, and purification company Pall has signed a new $7 million contract with contract development and manufacturing organization...
Danaher acquires Precision NanoSystems
Danaher has acquired Precision NanoSystems, a Canadian developer of genetic medicines including messenger RNA vaccines.
Cytiva acquires Vanrx Pharmasystems
Cytiva has acquired Vanrx Pharmasystems, a Canadian-based company that makes robotic aseptic filling machines to fill vials, syringes, and cartridges.
Pall debuts solution for biotech research
Pall, one of the largest suppliers of laboratory filtration and clarification products, recently launched two new filtration and clarification plates...

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter